Tweet
<img alt="" height="1" width="1" />
Merck's Vorapaxar Gets Positive FDA Review
Forbes
A few years ago a novel antiplatelet agent from Merck seemed all but dead. Vorapaxar, a thrombin receptor antagonist, was widely thought to have no future after unacceptably high serious bleeding rates were found in two large clinical trials studying the drug ...
Merck rises ahead of anticlotting drug reviewBusinessweek
Merck gets boost from announcement it will seek early approval for cancer drugThe Star-Ledger - NJ.com
FDA Review Endorses Vorapaxar Approval in Prior MI PatientsMedscape
Bloomberg -Financial Times -Reuters
all 19 news articles »
More...